ABSTRACT

Background: Two comprehensive R surveillance programs (LEADER and ZAAPS) have monitored linezolid (LZD) activity for over 8 years in the USA and over 20 other nations; approximately 12,000 clinical Gram-positive (GP) samples/year. Overall results are analyzed for evolving R rates and mechanism types, where detected.

Methods: A total of 12,168 isolates (6,414/5,754 from USA/ex-USA) were susceptibility (S) tested by CLSI methods (M07-A8) collected from 123 hospitals in 23 countries in 2009. Six major GP pathogen groups were sampled: S. aureus (6,215; 37.9 to 51.4% [USA] MRSA), coagulase-negative staphylococci (CoNS; 1,643), enterococci (ENT; 1,761), S. pneumoniae (SPN; 1,297), viridans group (VGS; 478) and β-haemolytic (BHS; 776). GF strains with LZD-non-S (MIC, $\geq 4 \mu g/mI$) were validated and R mechanisms determined by molecular methods.

Results: All SPN, VGS and BHS were LZD-S and had modal/MIC₉₀ values at 1 µg/ml. Among *S. aureus*, 5 LZD-R strains (USA only; 0.15%) were noted in 5 states having the following R mechanisms: cfr (2), G2576T (2) and L3 S145 deletion (1). LZD-R CoNS were noted in USA (12; 1.47%) and ex-USA (4; Mexico and Italy, 0.48%) with the following R-mechanisms: cfr (6; 2 combined with L3 alterations), G2576T (6) and L3/L4 mutations (4). LZD MIC₉₀ results were stable at 1 and 2 µg/ml for SA and CoNS, respectively. LZD-R among ENT were dominantly in E. faecium (11/12 strains; 0.54-0.79% by region), and produced by G2576T (11) or a single L4 (F101L) mutation (1); isolated in USA, Germany, Korea and China. R rates are declining in GP for the LEADER (0.45 [2006] to 0.34% [2009]) and ZAAPS (0.19 to 0.14%) Programs. Clonal outbreaks are frequent factors in LZD-R occurrences worldwide. Clindamycin inducible R in SA was 37.9%, encouraging use of D-testing.

	LZD MIC distributions (cum. %) for all tested strains						
Pathogen/Regional sample (no.)	≤0.25	0.5	1	2	4	8	%R ^a
S. aureus							
USA (3,257)	0.3	0.9	41.5	99.8	99.9	>99.9	0.15
ZAAPS (2,958) ^b	0.1	1.3	37.5	100.0	-	-	0.00
CoNS							
USA (816)	1.5	37.1	94.4	98.3	98.5	98.9	1.47
ZAAPS (827)	0.9	25.9	94.1	99.3	99.5	99.6	0.48
ENT							
USA (1,017)	0.1	4.0	53.4	98.9	99.2	99.6	0.79
ZAAPS (744)	0.0	4.3	51.5	99.5	99.5	99.7	0.54
a. CLSI and EUCAST criteria.							

ZAAPS = ex-USA (32 nation sample)

Conclusion: Yearly LZD-R monitoring documents rare isolation of strains, usually CoNS and E. faecium. Numerous R-mechanisms have been detected, but the overall rates have remained stable in sampled nations since 2006 (<0.5% overall LZD-R).

INTRODUCTION

Over the past eight years, two surveillance programs have monitored emerging linezolid resistance, the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program for Asia-Pacific, Europe, Latin America, Canada and the LEADER Program (United States [USA]). Linezolid, the first oxazolidinone class agent to be licensed for clinical use, has been used primarily to treat multidrug-resistant (MDR) Grampositive pathogens found in complicated skin and soft tissue infections (cSSTI) and nosocomial pneumonias, after its USA Food and Drug Administration (FDA) approval in early 2000. Those Gram-positive pathogens that linezolid has excellent activity against include organisms such as methicillin-resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumoniae and vancomycin-resistant enterococci (VRE). Linezolid use continues to increase worldwide and the need for potency and resistance surveillance becomes vital to the continued success of the oxazolidinone class.

The linezolid mechanism of action has been described as binding to the 50S ribosomal subunit of the 23S rRNA molecule with inhibition of protein synthesis. Among the rare cases of linezolid resistance reported to date among staphylococci and enterococci, G2576U or G2447T target site mutations have been the detected mechanism, however, a mobile resistance element (*cfr*) has been described in staphylococci.

MATERIALS AND METHODS

Organism collection. A total of 12,168 Gram-positive isolates were forwarded to the central monitoring site (JMI Laboratories, North Liberty, Iowa, USA) from 23 nations and 123 medical centers. Each participating site in the USA fowarded a target total of 100 clinically significant Grampositive isolates in a prevalence style sampling design. Outside of the USA, multiple centers contributed designated numbers of strains for a total of 200 Gram-positive isolates per country.

Isolates were grouped for analysis as follows: S. aureus (6,215 strains), coagulase-negative staphylococci (CoNS; 1,643 strains), β -haemolytic streptococci (776 strains), viridans group streptococci (478 strains), S. pneumoniae (1,295 strains) and enterococci (1,761 strains). All processed organisms were identified by the submitting laboratory and confirmed by the central facility using the Vitek standard system (bioMerieux, Hazelwood, Missouri, USA) or molecular methods, when needed.

Summary of 2009 Oxazolidinone Resistance Surveillance Studies Worldwide (LEADER and ZAAPS Programs)

RN JONES, RE MENDES, DJ FARRELL, HS SADER, JE ROSS JMI Laboratories, North Liberty, Iowa, USA

<u>Susceptibility testing</u>. Antimicrobial susceptibility testing was performed using validated microdilution panels with cationadjusted Mueller-Hinton broth (2-5% lysed horse blood added for testing streptococci) prepared by TREK Diagnostics (Cleveland, Ohio, USA). The categorical interpretations of MIC results followed Clinical and Laboratory Standards Institute (CLSI) document M100-S20-U. Quality control (QC) organism (S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212 and S. pneumoniae ATCC 49619) results were within the acceptable MIC QC ranges as published by CLSI (2010).

All isolates were tested against antimicrobial agents active against Gram-positive organisms including: linezolid ciprofloxacin, erythromycin, levofloxacin, penicillin, quinupristin/dalfopristin, rifampin, teicoplanin, and vancomycin. Other drugs tested against selected pathogen subgroups were: ampicillin, ceftriaxone, clindamycin, piperacillin/tazobactam, tetracycline, and trimethoprim/sulfamethoxazole (TMP/SMX).

All linezolid-resistant isolates (MIC, $\geq 8 \mu g/mL$), if detected, were confirmed by Etest (bioMerieux) and disk diffusion methods. The determination of the domain V 23S ribosomal target mutation(s) was performed by polymerase chain reaction (PCR) amplification and sequence analysis. Furthermore, molecular tests to identify the *cfr* gene encoding resistances to oxazolidinones in staphylococci were tested as described by Mendes et al, [2008]. Other potential target site modifications (L3 and L4) associated with increased linezolid MIC results were also examined.

RESULTS

- The total number of Gram-positive cocci submitted to the ZAAPS and LEADER Programs was over 12,000 during 2009. All tests were performed in a reference laboratory by standardized CLSI methods (Tables 1-2 and Figure 1).
- Overall MRSA rates were 37.9% in the ZAAPS study and 51.4% in the LEADER study. Resistance to methicillin did not adversely affect the linezolid activity (data not shown).
- Linezolid activity among CoNS was the same for the two programs with the MIC_{50/90} results at 1 μ g/ml. However, twelve isolates in LEADER Program and four isolates in ZAAPS Program were found to have linezolid MIC results of $\geq 8 \mu g/ml$ (14 S. epidermidis, 1 S. cohnii and 1 S. capitis; Table 2). Overall linezolid resistance rates were only 0.48% (ZAAPS) and 1.47% (LEADER).
- The VRE rate was 11.7% in ZAAPS (highest rate in Taiwan, 41.5%) and 29.0% in LEADER (highest rate in Mid-Atlantic Census Region, 41.3%). Overall linezolid resistance was 0.5% (4 strains; ZAAPS) and 1.1% (8 strains; LEADER).

- in 2008).

methods.

Pathogen (No. of isolates ZAPS/LEADER) Antimicrobial agent ZAAPS/LEADER % Susceptible* % Susceptible* S. aureus (2.958/3.257) Linezolid Oxacilin 1/2 2/2 100.0799.8 100.0799.8 S. aureus (2.958/3.257) Oxacilin 1/2 2/2 100.0799.8 100.0799.8 Chindamyoin Gentamicus Levolfoxacin 0.55/2 >2/2 22.148.6 52.148.6 Chindamyoin Gentamicus 0.55/2.5 >2/2.2 73.798.0 75.3 98.0 Tetrazyoline 50.55/0.5 >4/3.4 64.8/57.4 64.8/57.4 Tetrazyoline 50.55/0.5 >4/3.4 64.8/57.4 64.8/57.4 Tetrazyoline 50.55/0.5 >4/3.4 64.8/57.4 64.8/57.4 Tetrazyoline 50.55/0.5 >2/3.2 98.5 99.5/98.5 Chindamyorin 0.25/0.25 >2/3.2 98.4/8.1 19.8/26.1 Cons ⁵ Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 Cons ⁵ Linezolid 1/1 1/2 100.1/100.0 100.0/100.0 C			MIC (µg/ml):		CLSI	EUCAST	
(No. 01 Bodales) agent 50% 90% ZAAPS/LEADER ZAAPS/LEADER ZAAPS/LEADER S. aureus Linezolid 2/2 2/2 100.0/99.8 100.0/99.8 (2,958/3,257) Oxacillin 1/2 2/2 2/2 100.0/99.8 100.0/99.8 (2,958/3,257) Oxacillin 1/2 2/2 56.6/3.69 56.4/37.2 Cinidamycin 0.55/6.25 >2/2 7.4/48.6 62.1/48.6 62.1/48.6 Gentamicin 50/5.0 >4/2.4 64.8/57.4 64.8/57.4 64.8/57.4 Levofloxacin 50/5.0 >4/2.4 64.8/95.3 77.3/95.0 77.8/95.0 Vancomycin 1/1 1/1 100.0/100.0 100.0/100.0 100.0/100.0 CoNS* Linezolid 1/1 1/1 19.8/261 19.8/261 19.8/261 CoNS* Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 Gentamicin 4/2 >8/0.8 50.1/67.3 63.4/661 0.2/9.9 Condamycin 0.2/9.02 <td>Pathogen</td> <td>Antimiershiel</td> <td colspan="2">ZAAPS/LEADER</td> <td>% Susceptible^a</td> <td colspan="2">% Susceptible^a</td>	Pathogen	Antimiershiel	ZAAPS/LEADER		% Susceptible ^a	% Susceptible ^a	
S. aureus Linezolid 2/2 2/2 100.0/198.8 100.0/198.6 (2,956/3,257) Oxacilin 1/2 >2/2> 62.1/148.6 62.1/148.6 (2,956/3,257) Daptomycin 0.56/5.2 >2/2> 75.7/198.4 75.3/198.0 Daptomycin 0.56/0.5 >2/2/2 >8/5.2 77.7/198.4 75.3/198.0 Levofloxacin 0.5/15.0 >4/4.4 44.8/157.4 64.8/157.4 64.8/157.4 Tetracycline 52/52 >8/5.2 77.9/155.9 77.3/195.0 79.9/10.0 CONS* Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 CONS* Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 Gertamicin 4/52 >2/2> 2/2 18.7/26.1 19.8/26.1 Daptomycin 0.25/0.25 0.5/0.5 100.0/100.0 100.0/100.0 Gertamicin 4/52 >8/2 8/2 11.8/2 16.6/1 Daptomycin 0.25/0.25 >2/2 20/2 60.1/16.28/16.1 <	(NO. OF ISOIATES ZAAPS/LEADER)	agent	50%	90%	ZAAPS/LEADER	ZAAPS/LEADER	
(2,959/3,257) Oxacillin 1/52 >2/52 65.6 / 36.9 56.4 / 37.2 Clindamycin 0.5/5/2 >2/52 75.6 / 36.9 72.4 / 80.4 72.0 / 79.7 Daptomycin 0.5/0.5 >2/52 75.7 / 98.4 75.3 / 98.0 Levofloxacin 50.5/60.5 >4/54 64.8 / 57.4 64.8 / 55.2 94.8 / 95.5 94.8 / 95.5 95.5 / 95.5 65.6 / 50.5 52.2 / 52.2 38.4 / 23.1 36.4 / 33.6 73.3 / 63.4 / 68.1 53.2 / 52.2 / 52.2 50.5 / 50.5 50.6 / 50.7 / 50.2 / 5	S. aureus	Linezolid	2/2	2/2	100.0 / 99.8	100.0 / 99.8	
Erythromycin 0.5/>2 >2/>2 55.6 / 36.9 56.4 / 37.2 Diptomycin 0.5/0.5 >2/2 72.4 / 80.4 72.0 / 79.7 Daptomycin 0.5/0.5 >2/0.5 100.0 / 100.0 100.0 / 100.0 Gentamicin £2/2.2 >8/52 75.7 / 88.4 75.3 / 98.0 Tetracycline £2/2.5 >4/54 64.8 / 57.4 64.8 / 57.4 64.8 / 57.4 Tetracycline £2/2.5 \$2.6 / 20.5 94.8 / 88.5 94.8 / 86.5 94.8 / 86.5 Vancomycin 1/1 1/1 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 CoNS* Linezolid 1/1 1/1 198.7 / 26.1 198.8 / 26.1 198.7 / 26.1 (277616) Oxacillin >2.0 / 20.25 >2.0 / 20.5 65.1 / 67.3 63.4 / 66.1 Daptomycin 0.2 / 20.25 >2.0 / 20.5 68.1 / 67.3 63.4 / 66.1 Levofloxacin 4/4 -4/-4 44.0 / 43.6 44.9 / 45.4 44.0 / 43.6 Levofloxacin 2/12 >10/2 100.0 / 100.0 100.7 / 100.0<	(2,958/3,257)	Oxacillin	1/>2	>2/>2	62.1 / 48.6	62.1 / 48.6	
Clindamycin 50.25/50.25 >2/2.2 72.4 / 80.4 72.0 / 79.7 Daptomycin 0.50.5 >2/2.5 75.7 / 98.4 75.3 / 98.0 Gentamicin 22/22 >8/2.2 75.7 / 98.4 75.3 / 98.0 Tetracycline 22/22 >8/2.2 77.9 / 95.9 77.3 / 95.0 TMP/S/MX* 20.5/20.5 >0.5/20.5 94.8 / 98.5 94.8 / 98.5 Vancomycin 1/1 1/1 100.0 100.0 / 100.0 CoNS* Linezolid 1/1 1/1 99.5 / 98.5 99.5 / 98.5 / 98.5 E2/21 28.2 22 >2/2.2 36.4 / 33.1 36.4 / 33.6 E1/21 18.8 / 25.1 E7/21 28.5 99.5 / 98.5 / 98.5 / 98.5 / 98.5 E2/21 28.2 22/22 36.4 / 33.1 36.4 / 33.6 Clindamycin 52/5/2 25 22/2.2 36.4 / 33.1 36.4 / 33.6 Clindamycin 52/5/2 25 0.5/0.5 100.0 / 100.0 / 100.0 / 100.0 / 100.0 Gentamicin 4/4 >4/2.4 44.0 / 43.6 44.0 / 43.6 E1/21 28.2 29.2 29.2 20/2.2 36.4 / 33.1 36.4 / 46.1 (59.4 Levofloxacin 4/4 >4/2.4 44.0 / 43.6 44.0 / 43.6 E1/21 29.2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 98.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/5/16 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin 3/4/4 >4/3/4 48.4 45.4 - / - Tetracycline 22/5/2 >16/5/16 64.7 / 16.8 62.8 / 67.6 Ciprofloxacin 3/4/4 >4/3/4 48.4 45.4 - / - Tetracycline 38/58 >8/5/8 39.1 / 13.4 * -/ - Ciprofloxacin 3/4/4 >4/3/4 18.1 * -/ - Ciprofloxacin 3/4/4 >4/3/4 18.1 * -/ - Ciprofloxacin 3/4/4 >3/5/3 1.30.4 * -/ - Tetracycline 38/58 >8/5/8 39.1 / 100.0 / 100		Erythromycin	0.5/>2	>2/>2	55.6 / 36.9	56.4 / 37.2	
Captalaniyan 0.302/52 >20/52 75.7 / 98.4 75.3 / 98.0 Levoltoxacin s0.5/50.5 >4/54 64.8 / 57.4 64.8 / 57.4 64.8 / 57.4 Tetracycline s2/52 >4/52 77.9 / 95.9 77.3 / 95.0 77.3 / 95.0 TMP/SMX* s0.5/50.5 s0.5/50.5 94.8 / 98.5 94.8 / 98.5 94.8 / 98.5 CoNS* Linezolid 1/1 1/1 99.6 / 98.5 99.8 / 59.8 / 98.5 CONS* Linezolid 1/1 1/1 1/1 99.5 / 98.5 98.6 / 98.5 Captomycin 0.25/0.25 >2/5-2 95.1 / 67.3 63.4 / 66.1 Daptomycin 0.25/0.25 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Gentamicin 4/52 >8/5.8 51.0 / 73.4 46.4 / 69.4 Levoltoxacin 4/4 ×4/5.4 ×4.0 / 43.5 67.6 Tetracyceline 52/52 >80.8 / 88.5 28.7 / 65.0 71.2 Tetracyceline 52/52 >80.8 / 98.1 30.3 / 73.9 -/- Tetracyceline			≤0.25/≤0.25	>2/>2	72.4 / 80.4	72.0779.7	
Levolitoxacin 50.5/s0.5 >4/s4 64.8 / 57.4 64.8 / 57.4 Tetracycline 52/s2 >8/s2 77.9 / 98.9 77.3 / 95.0 TMP/SMX* 50.5/s0.5 S0.5/s0.5 94.8 / 98.5 94.8 / 98.5 Vancomycin 1/1 1/1 100.0 / 100.0 100.0 / 100.0 CoNS* Linezolid 1/1 1/1 109.5 / 98.5 98.6 / 98.5 (827/816) Oxacillin >2/s2 >2/s2 2/s2 64.7 / 67.3 63.4 / 66.1 Daptomycin 0.25/0.25 0.5/0.5 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 Gentamicin 4/s2 >4/s4 44.0 / 43.6 44.0 / 43.6 46.4 / 67.4 Levofloxacin 4/s2 >8/s8 51.0 / 73.4 46.4 / 69.4 1.8 / 80.7 ThtP/SMX% 50.5/s0.5 >2/s2 20.8 / 86.8 / 85.7 62.8 / 60.1 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 7.4 Enterococci Linezolid 1/1 2/2 98.5 / 98.9		Gentamicin	<2/<2	>2/0.5	75 7 / 98 4	75 3 / 98 0	
Tetracycline ≤2/≤2 >8/≤2 77.9 / 95.9 77.3 / 95.0 TMP/SMX ^b ≤0.5/≤0.5 ≤0.5/≤0.5 94.8 / 98.5 94.8 / 98.5 Vancomycin 1/1 1/1 99.5 98.5 99.5 / 98.5 CoNS ^c Linezolid 1/1 1/1 99.5 / 98.5 99.5 / 98.5 (827/816) Oxacillin >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 Cindamycin 0.25/0.25 >2/>2 36.4 / 33.1 36.4 / 46.1 Daptomycin 0.25/0.25 >2/>2 36.4 / 33.4 44.4 / 64.4 Levoltoxacin 4/4 4/-4 44.0 / 43.6 44.0 / 43.6 Tetracycline \$2/≤2 >8/-8 86.1 / 67.8 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Tetracycline \$2/≤2 \$2/8 86.8 85.2 81.5 / 81.7 Tetracycline \$4/>4 >4/2 40.4 44.9 4.4 4.6 4.7 (744/1.017) Ampicillin \$2/2		Levofloxacin	<0.5/<0.5	>4/>4	64 8 / 57 4	64 8 / 57 4	
TMP/CRMX* S0.5/s0.5 s0.5/s0.5 94.8 / 98.5 94.8 / 98.5 Vancomycin 1/1 1/1 100.0 / 100.0 100.0 / 100.0 CoNS* Linezolid 1/1 1/1 195.7 / 98.5 99.5 / 98.5 (827/816) Oxaciliin >2/>2 >2/>2 2/>2 36.4 / 33.1 36.4 / 33.6 Cindamycin >2/50.25 >2/>2 36.4 / 33.1 36.4 / 43.6 Daptomycin 0.25/0.25 >2/>2 86.8 10.0 / 100.0 100.0 / 100.0 Gentamicin 4/s2 >8/>8 86.8 / 85.2 81.5 / 81.7 TMP/SMX* 50.5/0.5 >2/>2 86.8 / 85.2 81.5 / 81.7 Tetracycline \$2/s2 >8/>8 86.8 / 85.2 81.5 / 81.7 TMP/SMX* 50.5/0.5 >2/>2 80.6 86.7 82.8 / 60.1 46.4 / 69.4 Vancomycin 1/1 2/2 99.5 / 98.9 99.5 / 98.9 99.5 / 98.9 99.5 / 98.9 99.5 / 98.9 99.5 / 98.9 99.5 / 98.9 71.2 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0		Tetracycline	≤2/≤2	>8/≤2	77.9 / 95.9	77.3 / 95.0	
Vancomycin 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (827/816) Oxacillin >2/>2 >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 (827/816) Oxacillin >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 Clindamycin >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 Ogentamicin 4/>2 >2/>2 36.4 / 33.1 36.4 / 46.1 Daptomycin 0.25/0.25 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Gentamicin 4/ >4/>4 44.0 / 43.6 44.0 / 43.6 Levofloxacin 4/4 >4/>4 44.0 43.6 40.7 3.6 Tetracycline \$2/>2 >8/>8 86.8 / 85.2 81.5 / 61.7 TMP/SMX* \$0.5/\$0.5 >2/>2 \$2.8 / 60.1 \$2.8 / 60.1 Vancomycin 1/1 2/2 100.0 / 100.0 98.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/>516 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin >4/>4 >4/>4 48.8 /		TMP/SMX ^b	≤0.5/≤0.5	≤0.5/≤0.5	94.8 / 98.5	94.8 / 98.5	
CoNS ^e Linezolid 1/1 1/1 1/1 99.5 / 98.5 99.5 / 98.5 (827/816) Oxacilin >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 Cindamycin >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 Daptomycin >2/>2/>2 >2/>2 36.4 / 33.6 36.4 / 66.1 Daptomycin 0.25/0.25 >/>2/>2 36.8 51.0 / 73.4 46.4 / 69.4 Levofloxacin 4/4 >4/>4 44.0 / 43.6 44.0 / 43.6 44.0 / 43.6 Tetracycline 52/≤2 >8/×8 86.8 / 85.2 81.5 / 81.7 TMP/SMX* Ciprofloxacin >4/>4 >4/>4 40.0 / 43.6 46.7 / 68 28.7 / 99.5 / 99.9 Ciprofloxacin >4/>4 >4/>4 33.9 / 37.9 - / - 26.8 / 67.6 Ciprofloxacin >4/>4 >4/>4 48.8 / 81.4 - / - Tetracycline >8/>8 83.1 / 30.4 - / - Tetracycline >8/>28/>8 39.1 / 30.4 - / - Tetracycline >8/>28/>8<		Vancomycin	1/1	1/1	100.0 / 100.0	100.0 / 100.0	
(827/816) Oxacillin >2/>2 >2/>2 19.8 / 26.1 19.8 / 26.1 Erythromycin >2/>2 >2/>2 2/>2 36.4 / 33.1 36.4 / 33.6 Clindamycin <0.25/0.25 >2/>2 65.1 / 67.3 65.4 / 66.1 Daptomycin 0.25/0.25 >2/>2 65.1 / 67.3 65.4 / 66.1 Daptomycin 0.25/0.25 >2/>2 65.1 / 67.3 46.4 / 69.4 Levofloxacin 4/4 >4/>4/>4 44.0 / 43.6 44.0 / 43.6 Tetracycline 22/>2 >8/>8 65.0 17.3 4 46.4 / 69.4 Levofloxacin 4/4 >4/>2 >8/>8 65.0 15.2 81.5 / 81.7 TMP/SMX* 50.5/s0.5 >2/>2 62.8 / 60.1 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 99.5 / 99.2 (744/1.017) Ampicillin 2/2 >16/>16 64.7 / 67.8 62.8 / 67.6 Daptomycin 1/1 2/2 100.0 / 100.0 88.5 / 99.1 Levofloxacin >4/>4 ×4/>4 44.8 / 45.4 - /- Tetracycline >8/>8 >8/>8 39.1 / 30.4 -/- Tetracycline >8/>8 >8/>8 39.1 / 30.4 -/- Tetracycline >8/>8 >8/>8 39.1 / 30.4 -/- Tetracycline >2/5/20.25 >2/>2 50.8 / 58.1 50.8 / 58.7 7 Amox/clav ≤11/×1 8/8 81.1 / 81.8 -/- Ceftriaxone ≤0.25/50.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin ≤0.25/50.25 >2/>2 60.2 / 77.8 61.3 / 78.4 Levofloxacin 1/1 2/1 98.3 / 99.1 98.3 / 99.1 Tetracycline ≤0.25/50.25 0.5/>2 50.2 56.2 / 63.7 62.4 / 67.2 Vancomycin 0.5/0.5 0.5/0.5 00.0 / 100.0 100.0 / 100.	CoNS⁰	Linezolid	1/1	1/1	99.5 / 98.5	99.5 / 98.5	
Erythromycin >2/>2 >2/>2 36.4 / 33.1 36.4 / 33.6 Clindamycin 0.25/0.25 >2/>2 65.1 / 67.3 63.4 / 61.1 Daptomycin 0.25/0.25 0.5/0.5 100.0 / 100.0 / 100.0 / 100.0 Gentamicin 4/52 >8/>8 85.10 / 73.4 46.4 / 69.4 Levofloxacin 4/4 >4/>4.4 44.0 / 43.6 44.0 / 43.6 Tetracycline 52/52 >8/>8 86.8 / 85.2 81.5 / 81.7 TMP/SMX ^b 50.5/s0.5 >2/>2 62.8 / 60.1 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 99.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/>16 64.7 / 67.8 62.8 / 67.6 Daptomycin 1/1 2/2 100.0 / 99.9 - / - Levofloxacin >4/>4 >4/>4 >4/>4 44.8 / 45.4 - / - Tetracycline 8/>4 >4/>4 >4/>4 33.9 / 37.9 - / - ^c Daptomycin 1/1 2/2 100.0 / 99.9 - / - Levofloxacin >4/>4 >4/>4 >4/>4 48.8 / 45.4 -/ - Tetracycline 8/>8 8/×6 39.1 / 30.4 - / - Tetracycline 8/>8 8/×6 39.1 / 30.4 - / - Tetracycline 20.25/s0.25 2/>2 8/>16 90.3 / 71.8 89.5 / 71.2 Vancomycin 1/2 >16/>16 87.4 / 70.3 87.4 / 70.3 S. pneumoniae Linezolid 1/1 1/1 100.0 100.0 100.0 / 100.0 100.0 / 100.0 (00.0 / 100.0 (00.6 / 100.0 - (636/659) Penicillin ⁴ 50.03/s0.03 4/4 56.8 / 57.7 56.8 / 57.7 Cettriaxone 50.25/s0.25 2/2 80.5 / 87.1 67.8 / 77.2 Erythromycin 10.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 50.8 / 58.1 Clindamycin 50.25/s0.25 >2/>2 50.8 / 58.3 0 / 75.9 53.0 / 75.9 TMP/SMX ^b ≤0.5/s0.5 >2/>2 50.25/s0.25 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 1	(827/816)	Oxacillin	>2/>2	>2/>2	19.8 / 26.1	19.8 / 26.1	
Clindamycin 50/25/90/25 >2/>2 65.1 / 67.3 63.4 / 66.1 Daptomycin 0.25/0.25 0.5/0.5 100.0 / 100.0 / 100.0 / 100.0 Gentamicin 4/52 >8/>8 65.1 0 / 73.4 46.4 / 69.4 Levofloxacin 4/4 >4/>4 44.0 / 43.6 44.0 / 43.6 Tetracycline 52/52 >8/>8 86.8 / 85.2 81.5 / 81.7 TMP/SMX* 50.6/50.5 >2/>2 62.8 / 60.1 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 99.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/>16 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin >4/>4 >4/>4 33.9 / 37.9 - / - ^c Daptomycin 1/1 2/2 100.0 / 99.9 - /- Levofloxacin >4/>4 >4/>4 44.8 / 45.4 - /- Tetracycline >8/>8 >8/>8 39.1 / 30.4 -/- Tetracycline >8/>8 >8/>8 39.1 / 30.4 89.5 / 71.2 Vancomycin 1/2 >16/>16 87.4 / 70.3 87.4 / 70.3 S. pneumoniae Linezolid 1/1 1/1 100.0 / 100.0 / 100.0 / 100.0 / 100.0 / 100.0 (636/659) Penicillin ^d 50.03/50.03 4/4 56.8 (57.7 56.8 / 57.7 Amox/clav ≤1/≤1 8/8 81.1 / 81.8 -/- Cettriaxone \$0.25/\$0.25 2/2 80.5 / 81.1 50.8 / 58.1 Clindamycin 50.25/\$0.25 2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin 50.25/\$0.25 2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin \$0.25/\$0.25 2/>2 50.8 / 58.1 50.8 / 58.1 20.8 / 58.1 Clindamycin \$0.25/\$0.25 2/>2 50.8 / 58.1 50.8 / 58.1 1.9 / 78.4 / 67.2 Vancomycin \$0.25/\$0.25 2/>2 50.8 / 68.7 / 58.4 / 67.7 Clindamycin \$0.25/\$0.25 2/>2 50.8 / 68.7 / 58.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 67.2 / 78.4 / 72.8 / 78.4 / 70.3 80.8 / 86.4 / 72.2 / 78.4 / 72.8 / 78.4 / 72.4 / 67.2 / 78.4 / 72.3 80.8 / 86.4 / 72.2 / 78.4 / 72.2 / 78.4 / 72.2 / 78.4 / 72.2 / 78.4 / 72.3 80.8 / 86.4 /		Erythromycin	>2/>2	>2/>2	36.4 / 33.1	36.4 / 33.6	
Daplomycin 0.23/0.25 >3/0.5 510.07/100.0 100.07/100.0 Gentamicin 4/4 >4/5.4 44.0/43.6 44.0/43.6 Terracycline 22/52 >8/5.8 86.8 85.2 81.5/81.7 TMP/SMX ^b ≤0.5/50.5 >2/>2 62.8 60.1 62.8/60.1 Vancomycin 2/1 2/2 99.5 99.9 99.5/99.2 (744/1,017) Ampicillin 2/2 >16/5/16 64.7/67.8 62.8/67.6 Ciprofloxacin >4/>4 >4/>4/3 39.79.9 -/-* Daptomycin 1/1 2/2 100.0/100.0 99.9 -/- Levofloxacin >4/>4 >4/54 44.8/45.4 -/- Tetracycline ≤8/58 >8/5.8 39.1/30.4 -/- Tetracycline ≤8/52 ≥8/58 39.1/30.4 -/- Tetracycline ≤8/57.7 56.8/57.7 56.8/57.7 S.pneumoniae Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 (63/6		Clindamycin	≤0.25/≤0.25	>2/>2	65.1/67.3	63.4 / 66.1	
Levofloxacin 4/4 >4/->4/->4/->4/->4/->4/->4/->4/->4/->4/-		Gentamicin	0.25/0.25	0.5/0.5	100.07 100.0 51 0 / 73 <i>/</i>	100.07 100.0	
Tetracycline ≤2/≤2 >8/>6 86.8 / 85.2 81.5 / 81.7 TMP/SMX ^b ≤0.5/s0.5 >2/>2 62.8 / 60.1 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 99.5 / 99.2 (744/1,017) Ampicillin 2/2 16/>16 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin >4/>4 >4/>4 33 / 37.9 - / - Levofloxacin >4/>4 >4/>4 44.8 / 45.4 - / - Tetracycline >8/>8 39.1 / 30.4 - / - Tetracyclinin ≤2/s2 8/>16 90.3 / 71.8 89.5 / 7.7 Vancomycin 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (63/659) Penicillin ^d 50.03/s0.03 4/4 56.8 / 57.7 56.8 / 57.7 Amox/clav ≤1/s1 8/8 81.1 / 81.8 - / - Ceftriaxone ≤0.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Cl		Levofloxacin	4/32 4/4	>4/>4	44 0 / 43 6	44.0/43.6	
TMP/SMX ^b ≤0.5/s0.5 ≥2/>2 62.8 / 60.1 62.8 / 60.1 Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 98.9 99.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/>14 33.9 / 37.9 - / - ^c Daptomycin 1/1 2/2 100.0 / 100.0 99.5 / 99.2 Tetracycline >4/>4 43.9 / 37.9 - / - ^c Daptomycin 1/1 2/2 100.0 / 100.0 99.9 Tetracycline >8/>6 8 39.1 / 30.4 - / - Tetracycline >8/>6 8 39.1 / 30.4 - / - Tetracycline >2/>2 8/>16 90.3 / 71.8 89.5 / 71.2 Vancomycin 1/2 16/>16 87.4 / 70.3 87.4 / 70.3 S. pneumoniae Linezolid 1/1 1/1 100.00 100.0 100.0 (636/659) Penicillin ^d \$0.02/5/0.25 2/>2 \$0.6 / 87.7 \$6.8 / \$7.7 \$		Tetracycline	≤2/≤2	>8/>8	86.8 / 85.2	81.5 / 81.7	
Vancomycin 2/1 2/2 100.0 / 100.0 98.5 / 99.1 Enterococci Linezolid 1/1 2/2 99.5 / 99.2 99.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/5/16 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin >4/>4 >4/>4 33.9 / 37.9 - / - Daptomycin 1/1 2/2 100.0 / 99.9 - / - Levofloxacin >4/>4 >4/>4 8.8 / 58.3 39.1 / 30.4 - / - Tetracycline >8/>8 >8/>8 39.1 / 30.4 - / - - Vancomycin 1/2 >16/>16/516 87.4 / 70.3 87.4 / 70.3 S. pneumoniae Linezolid 1/1 1/1 100.0 100.0 / 100.0 (636/659) Penicillin ⁴ ≤0.03/50.03 4/4 56.8 / 57.7 56.8 / 57.7 Amox/clav ≤1/s1 8/8 81.1 / 81.8 - / - Ceftriaxone ≤0.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin ≤0.25/s0.25 >2/>2		TMP/SMX ^b	≤0.5/≤0.5	>2/>2	62.8 / 60.1	62.8 / 60.1	
Enterococci Linezolid 1/1 2/2 99.5 / 99.9 99.5 / 99.2 (744/1,017) Ampicillin 2/2 >16/>>16 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin >4/>4 >4/>4 3.9 / 37.9 - / -* Daptomycin 1/1 2/2 100.0 / 99.9 - / - Tetracycline >8/>8 >8/>8 39.1 / 30.4 - / - Tetracycline >8/>8 >8/>8 39.1 / 30.4 - / - Tetroplanin ≤2/s2 8/>16 90.3 / 71.8 89.5 / 71.2 Vancomycin 1/2 >16/>16 87.4 / 70.3 87.4 / 70.3 S. pneumoniae Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (636/659) Penicillin ^d ≤0.03/s0.03 4/4 56.8 / 57.7 56.8 / 57.7 Ceftriaxone ≤0.25/s0.25 >2/>2 80.5 / 87.1 67.8 / 77.2 Erythromycin ≤0.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin 50.25/s0.25 >2/>2 56.2 / 63.7 <td></td> <td>Vancomycin</td> <td>2/1</td> <td>2/2</td> <td>100.0 / 100.0</td> <td>98.5 / 99.1</td>		Vancomycin	2/1	2/2	100.0 / 100.0	98.5 / 99.1	
(744/1,017) Ampicillin 2/2 > 16/><16 64.7 / 67.8 62.8 / 67.6 Ciprofloxacin >4/>4 33.9 / 37.9 - / - Daptomycin 1/1 2/2 100.0 / 99.9 - / - Levofloxacin >4/>4 >4/>4 44.8 / 45.4 - / - Tetracycline >8/>8 8/>8 39.1 / 30.4 - / - Tetracycline >2/2 8/>16 90.3 / 71.8 89.5 / 71.2 Vancomycin 1/2 >16/>11 11 100.0 / 100.0 100.0 / 100.0 (636/659) Penicillind ≤0.03/≲0.03 4//4 56.8 / 57.7 56.8 / 57.7 Amox/clav ≤1/\$1 8/8 81.1 / 81.8 - / - Ceftriaxone ≤0.25/\$0.25 >2/>2 80.5 / 87.1 67.8 / 77.2 Erythromycin ≤0.25/\$0.25 >2/>2 80.3 / 99.1 98.3 / 99.1 Tetracycline ≤2/>8 ≤2/>8 53.0 / 75.9 53.0 / 75.9 Tetracycline ≤2/>8 ≤2/>2 56.2 / 63.7 62.4 / 67.2 Van	Enterococci	Linezolid	1/1	2/2	99.5 / 98.9	99.5 / 99.2	
Ciprofloxacin >4/>4 >4/>4 33.9 -/- Daptomycin 1/1 2/2 100.0/99.9 -/- Levofloxacin >4/>4 44.8/454 -/- Tetracycline >8/>8 >8/>8 39.1/30.4 -/- Teicoplanin ≤2/≤2 8/>16 90.3/71.8 89.5/71.2 Vancomycin 1/2 >16/>16 87.4/70.3 87.4/70.3 S. pneumoniae Linezolid 1/1 1/1 100.0 100.0/100.0 (636/659) Penicillin ^d ≤0.03/50.03 4/4 56.8/57.7 56.8/57.7 Amox/clav ≤11/51 8/8 81.1/81.8 -/- Ceftriaxone ≤0.25/s0.25 >2/>2 50.8/58.1 50.8/58.1 Clindamycin ≤0.25/s0.25 >2/>2 50.4/75.9 53.0/75.9 TMP/SMX ^b 50.5/s0.5 >2/>2 56.2/63.7 62.4/67.2 Vancomycin ≤1/≤1 ≤1/≤1 100.0/100.0 100.0/100.0 Streptococi Penicillin ≤0.25/s0.25 2	(744/1,017)	Ampicillin	2/2	>16/>16	64.7 / 67.8	62.8 / 67.6	
Daptomycin 1/1 2/2 100.0/99.9 -/- Levofloxacin >4/>4 >4/>4 44.8 / 45.4 -/- Tetracycline >8/>8 >8/>8 39.1 / 30.4 -/- Tetracycline >8/>8 >8/>8 39.1 / 30.4 -/- Vancomycin 1/2 >16/>16 87.4 / 70.3 87.4 / 70.3 S. pneumoniae Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (636/659) Penicillin ^d ≤0.03/s0.03 4/4 56.8 / 57.7 56.8 / 57.7 Armox/clav ≤1/s1 8/8 81.1 / 81.8 -/- Ceftriaxone ≤0.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 50.8 / 58.1 Clindamycin ≤0.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin ≤0.25/s0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin ≤0.25/s0.25 >2/>2 50.2 / 63.7 62.4 / 67.2 Urpthromycin ≤0.25/s0.25 >2/>2 56.2 / 63.7 62.4 / 67.2 Vancomycin 1/1 1/1		Ciprofloxacin	>4/>4	>4/>4	33.9/37.9	- / -c	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Daptomycin	1/1	2/2	100.0 / 99.9	- / -	
Teicoplanin 50/s0 30/s0 30/s0 30/s0 30/s0 30/s0 Teicoplanin 52/s2 8/s16 90.3/71.8 89.5/71.2 Vancomycin 1/2 >16/s16 87.4/70.3 87.4/70.3 S. pneumoniae Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 (636/659) Penicillin ^d ≤0.03/s0.03 4/4 56.8/57.7 56.8/57.7 Amox/clav ≤1/s1 8/8 81.1/81.8 -/- Ceftriaxone ≤0.25/s0.25 >2/s2 50.8/58.1 50.8/58.1 Clindamycin ≤0.25/s0.25 >2/s2 50.8/58.1 50.8/58.1 Clindamycin ≤0.25/s0.25 >2/s2 50.8/58.1 50.8/58.1 Clindamycin ≤0.25/s0.25 >2/s2 50.2/63.7 62.4/67.2 Vancomycin ≤1/s1 100.0/100.0 100.0/100.0 100.0/100.0 Streptococci Penicillin<<<0.05/s0.25		Levonoxacin	>4/>4	>4/>4	44.8/45.4	-/-	
Vancomycin 1/2 >16/>16 87.4/70.3 87.4/70.3 S. pneumoniae Linezolid 1/1 1/1 100.0/100.0 100.0/100.0 (636/659) Penicillin ^d ≤0.03/≤0.03 4/4 56.8/57.7 56.8/57.7 Amox/clav ≤1/≤1 8/8 81.1/81.8 -/- Ceftriaxone ≤0.25/≤0.25 >2/>2 80.5/87.1 67.8/77.2 Erythromycin ≤0.25/≤0.25 >2/>2 60.4/77.8 61.3/78.4 Levofloxacin 1/1 2/1 98.3/99.1 98.3/99.1 Tetracycline ≤2/>8 ≤2/>8 53.0/75.9 53.0/75.9 TMP/SMX ^b ≤0.5/≤0.5 >2/>2 56.2/63.7 62.4/67.2 Vancomycin ≤1/≤1 ≤1/±1 100.0/100.0 100.0/100.0 β-haemolytic Linezolid 1/1 1/1 100.0/100.0 80.7/10.0 (375/401) Ceftriaxone ≤0.25/≤0.25 20.25 100.0/100.0 80.4/82.8 Levofloxacin 1/≤0.5 1/1 98.1/99.5 90.9/96.8		Teiracycline	>0/>0 <2/<2	>0/>0 8/~16	00 3 / 71 8	-/- 805/712	
S. pneumoniae Linezolia 1/1 1/1 100.0		Vancomvcin	1/2	>16/>16	87.4 / 70.3	87.4 / 70.3	
(636/659) Penicillin ^d ≤0.03/≤0.03 4/4 56.8 / 57.7 56.8 / 57.7 Amox/clav ≤1/≤1 8/8 81.1 / 81.8 -/- Ceftriaxone ≤0.25/≤0.25 2/2 80.5 / 87.1 67.8 / 77.2 Erythromycin ≤0.25/≤0.25 >2/>2 50.8 / 58.1 50.8 / 58.1 Clindamycin ≤0.25/≤0.25 >2/>2 60.4 / 77.8 61.3 / 78.4 Levofloxacin 1/1 2/1 98.3 / 99.1 98.3 / 99.1 Tetracycline ≤2/>8 52/>2 56.2 / 63.7 62.4 / 67.2 Vancomycin ≤1/≤1 ≤1/≤1 100.0 / 100.0 100.0 / 100.0 steptococci Penicillin ≤0.015/0.03 0.06/0.06 100.0 / 100.0 100.0 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 >2/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 8 Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 / 96.8 8 Daptomycin 0.50/5.5 <td>S. pneumoniae</td> <td>Linezolid</td> <td>1/1</td> <td>1/1</td> <td>100.0 / 100.0</td> <td>100.0 / 100.0</td>	S. pneumoniae	Linezolid	1/1	1/1	100.0 / 100.0	100.0 / 100.0	
Amox/clav ≤1/≤1 8/8 81.1 / 81.8 - /- Ceftriaxone ≤0.25/≤0.25 2/2 \$0.5 / 87.1 67.8 / 77.2 Erythromycin ≤0.25/≤0.25 >2/>2 \$0.8 / 58.1 \$5.8 / 15.8 / 77.2 Erythromycin ≤0.25/≤0.25 >2/>2 \$6.4 / 77.8 \$61.3 / 78.4 Levofloxacin 1/1 2/1 98.3 / 99.1 98.3 / 99.1 Tetracycline ≤2/>8 \$2/>8 \$53.0 / 75.9 \$53.0 / 75.9 TMP/SMX ^b ≤0.5/≤0.5 >2/>2 \$66.2 / 63.7 \$62.4 / 67.2 Vancomycin ≤1/≤1 \$1/\$1 100.0 / 100.0 100.0 / 100.0 \$6.haemolytic Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 \$1/\$1 00.0 / 100.0 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 \$1/\$1 0.0 0 / 00.0 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 \$1/\$1 1/1 1/1 1/1 100.0 / 100.0 100.0 / 100.0 \$1/\$75/401 Ceftriaxone <td>(636/659)</td> <td>Penicillin^d</td> <td>≤0.03/≤0.03</td> <td>4/4</td> <td>56.8 / 57.7</td> <td>56.8 / 57.7</td>	(636/659)	Penicillin ^d	≤0.03/≤0.03	4/4	56.8 / 57.7	56.8 / 57.7	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Amox/clav	≤1/≤1	8/8	81.1 / 81.8	- / -	
$ \begin{array}{l c c c c c c c c c c c c c c c c c c c$		Ceftriaxone	≤0.25/≤0.25	2/2	80.5 / 87.1	67.8/77.2	
Clindamycin ≤0.25/s0.25 >2/>2 60.4 / 7.8 61.3 / 78.4 Levofloxacin 1/1 2/1 98.3 / 99.1 98.3 / 99.1 Tetracycline ≤2/>8 ≤2/>8 53.0 / 75.9 53.0 / 75.9 TMP/SMX ^b ≤0.5/s0.5 >2/>2 56.2 / 63.7 62.4 / 67.2 Vancomycin ≤1/≤1 ≤1/≤1 100.0 / 100.0 100.0 / 100.0 β-haemolytic Linezolid 1/1 1/1 1/1 100.0 / 100.0 100.0 / 100.0 streptococci Penicillin ≤0.015/0.03 0.06/0.06 100.0 / 100.0 80.8 / 100.0 (375/401) Ceftriaxone ≤0.25/s0.25 ≤0.25/s0.25 100.0 / 100.0 80.8 / 100.0 Erythromycin ≤0.25/s0.25 >2/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/s0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/±0.5 1/1 98.1 / 99.5 90.9 / 96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Vancomycin 0.5/0.5 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 1/1 00.0 / 100.0 - / - streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/s0.25 20.25/s0.25 90.2 / 88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/s0.25 50.25 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Clindamycin ≤0.25/s0.25 50.5 100.0 / 100.0 - / - Streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/s0.25 50.25 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Clindamycin ≤0.25/s0.25 50.25 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Daptomycin 0.5/0.5 1/1 100.0 / 99.6 - / - Vancomycin 0.5/0.5 - 1/1 00.0 / 99.6 - / - Vancomycin 0.5/0.5 - 1/1 00.0 / 99.6 - / -		Erythromycin	≤0.25/≤0.25	>2/>2	50.8 / 58.1	50.8 / 58.1	
Levolitoxacin 1/1 2/1 98.3 / 99.1 98.3 / 99.1 Tetracycline ≤2/>8 ≤2/>8 53.0 / 75.9 53.0 / 75.9 TMP/SMX ^b ≤0.5/≤0.5 >2/>2 56.2 / 63.7 62.4 / 67.2 Vancomycin ≤1/≤1 100.0 / 100.0 100.0 / 100.0 100.0 / 100.0 β-haemolytic Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 ≤0.25/≤0.25 100.0 / 100.0 80.8 / 400.0 (375/401) Ceftriaxone ≤0.25/≤0.25 0.5/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/50.5 1/1 98.1 / 99.5 90.9 /96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 - Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- Viridans group		Clindamycin	≤0.25/≤0.25	>2/>2	60.4 / 77.8	61.3 / 78.4	
TMP/SMX ^b ≤0/5/6 ≤2/26 53.0 / 75.9 53.0 / 75.9 TMP/SMX ^b ≤0.5/≤0.5 >2/>2 56.2 / 63.7 62.4 / 67.2 Vancomycin ≤1/≤1 100.0 / 100.0 100.0 / 100.0 β-haemolytic Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 ≤0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 >2/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 / 96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- Viridans group Linezolid 1/1 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1 88.8 / 91.7 82.7 / 89.4 Levofloxacin		Levonoxacin	1/1	2/1	98.3/99.1	98.3/99.1	
Vancomycin ≤1/≤1 ≤1/≤1 100.0 / 100.0 100.0 / 100.0 β-haemolytic Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 ≤0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 ≤0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 >2/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 / 96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Vancomycin 0.5/0.5 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- </td <td></td> <td></td> <td>≤2/20 <0.5/<0.5</td> <td>≤2/~0 \2/\2</td> <td>56.2/63.7</td> <td>55.0775.9 624/672</td>			≤2/20 <0.5/<0.5	≤2/~0 \2/\2	56.2/63.7	55.0775.9 624/672	
β-haemolytic Linezolid 1/1 1/1 100.0 / 100.0 100.0 / 100.0 streptococci Penicillin ≤0.015/0.03 0.06/0.06 100.0 / 100.0 100.0 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 ≤0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 Erythromycin ≤0.25/≤0.25 ≥0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 Erythromycin ≤0.25/≤0.25 >2/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 /96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Varcomycin 0.5/0.5 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Varidans group Linezolid 1/1 1/1 100.0 / 100.0 - Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/ - streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1		Vancomvcin	_0.0/_0.0 ≤1/≤1	<i>≤</i> 1/≤1	100 0 / 100 0	100.0 / 100.0	
Streptococci Penicillin ≤0.015/0.03 0.06/0.06 100.0 / 100.0 100.0 / 100.0 (375/401) Ceftriaxone ≤0.25/≤0.25 ≤0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 Erythromycin ≤0.25/≤0.25 ≥0.25/≤0.25 100.0 / 100.0 80.8 / 100.0 Erythromycin ≤0.25/≤0.25 >2/>2 81.1 / 62.8 81.1 / 62.8 Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 / 96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1 88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/≤0.25 ≤0.25/0.5 90.2 / 88.6 91.6 / 90.9 -/- Levofloxacin 1/1 2/2 95.8 / 90.2 -/-	β-haemolytic	Linezolid	1/1	1/1	100.0 / 100.0	100.0 / 100.0	
$\begin{array}{llllllllllllllllllllllllllllllllllll$	streptococci	Penicillin	≤0.015/0.03	0.06/0.06	100.0 / 100.0	100.0 / 100.0	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	(375/401)	Ceftriaxone	≤0.25/≤0.25	≤0.25/≤0.25	100.0 / 100.0	80.8 / 100.0	
Clindamycin ≤0.25/≤0.25 0.5/>2 89.8 / 81.8 90.4 / 82.8 Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 /96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Vancomycin 0.5/0.5 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/ - streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1 88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/≤0.25 ≤0.25/0.5 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Clindamycin ≤0.25/0.25 0.5/1 99.5 / 99.6 - / - Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Daptomycin 0.25/0.5 1/1 100.0 / 100.0 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010).		Erythromycin	≤0.25/≤0.25	>2/>2	81.1 / 62.8	81.1 / 62.8	
Levofloxacin 1/≤0.5 1/1 98.1 / 99.5 90.9 /96.8 Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Vancomycin 0.5/0.5 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1 88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/≤0.25 ≤0.25/0.5 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Clindamycin ≤0.25/0.25 0.5/1 99.5 / 99.6 - / - Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Vancomycin 0.5/0.5 1/1 100.0 / 99.6 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010).		Clindamycin	≤0.25/≤0.25	0.5/>2	89.8 / 81.8	90.4 / 82.8	
Daptomycin 0.12/0.12 0.25/0.25 100.0 / 100.0 100.0 / 100.0 Vancomycin 0.5/0.5 0.5/0.5 100.0 / 100.0 100.0 / 100.0 Viridans group Linezolid 1/1 1/1 100.0 / 100.0 -/- streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1 88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/≤0.25 2/1 >88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/≤0.25 ≤0.25/0.5 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Vancomycin 0.5/0.5 1/1 100.0 / 99.6 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c= no criteria published c= no criteria at ≤0.06 µg/ml for both organizations.		Levofloxacin	1/≤0.5	1/1	98.1 / 99.5	90.9/96.8	
Viridans group Linezolid 1/1 1/1 1/0.0 / 100.0 - / - streptococci Penicillin 0.06/0.06 1/1 71.0 / 77.3 80.8 / 86.4 (214/264) Ceftriaxone ≤0.25/≤0.25 2/1 88.8 / 91.7 82.7 / 89.4 Erythromycin ≤0.25/≤0.25 2/1 >2/>2 60.3 / 46.2 - / - Clindamycin ≤0.25/≤0.25 ≤0.25/0.5 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Vancomycin 0.5/0.5 1/1 100.0 / 99.6 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c = no criteria published c = no criteria published c = no criteria published c = no criteria at ≤0.06 µg/ml for both organizations.		Vancomycin	0.12/0.12	0.25/0.25	100.0 / 100.0	100.0 / 100.0	
streptococci Penicillin $0.06/0.06$ $1/1$ $71.0/77.3$ $80.8/86.4$ (214/264) Ceftriaxone $\leq 0.25/\leq 0.25$ $2/1$ $88.8/91.7$ $82.7/89.4$ Erythromycin $\leq 0.25/\leq 0.25$ $2/1$ $88.8/91.7$ $82.7/89.4$ Erythromycin $\leq 0.25/\leq 0.25$ $2/2$ $60.3/46.2$ $-/-$ Clindamycin $\leq 0.25/\leq 0.25$ $\leq 0.25/0.5$ $90.2/88.6$ $91.6/90.9$ Levofloxacin $1/1$ $2/2$ $95.8/90.2$ $-/-$ Daptomycin $0.25/0.25$ $0.5/1$ $99.5/99.6$ $-/-$ Vancomycin $0.5/0.5$ $1/1$ $100.0/99.6$ $100.0/100.0$ a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci $c=$ no criteria published $c=$ no criteria published $c=$ no criteria published $c=$ no criteria at $\leq 0.06 \ \mu g/ml$ for both organizations.	Viridans group		1/1	1/1	100.0 / 100.0	- / -	
$\begin{array}{llllllllllllllllllllllllllllllllllll$	streptococci	Penicillin	0.06/0.06	1/1	71.0 / 77.3	, 80.8 / 86.4	
Erythromycin $\leq 0.25/1$ $>2/>2$ $60.3 / 46.2$ $- / -$ Clindamycin $\leq 0.25/\le 0.25$ $\leq 0.25/0.5$ $90.2 / 88.6$ $91.6 / 90.9$ Levofloxacin $1/1$ $2/2$ $95.8 / 90.2$ $- / -$ Daptomycin $0.25/0.25$ $0.5/1$ $99.5 / 99.6$ $- / -$ Vancomycin $0.5/0.5$ $1/1$ $100.0 / 99.6$ $100.0 / 100.0$ a.Interpretive breakpoint criteria of the CLSI and EUCAST (2010).b.Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococcic. $-$ = no criteria publishedd.Criteria at $\leq 0.06 \mu$ g/ml for both organizations.	(214/264)	Ceftriaxone	≤0.25/≤0.25	2/1	88.8/91.7	82.7 / 89.4	
Clindamycin ≤0.25/≤0.25 ≤0.25/0.5 90.2 / 88.6 91.6 / 90.9 Levofloxacin 1/1 2/2 95.8 / 90.2 - / - Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Vancomycin 0.5/0.5 1/1 100.0 / 99.6 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c. - = no criteria published d. Criteria at ≤0.06 µg/ml for both organizations.		Erythromycin	≤0.25/1	>2/>2	60.3 / 46.2	- / -	
$\begin{array}{c cccc} Levofloxacin & 1/1 & 2/2 & 95.8 / 90.2 & -/-\\ Daptomycin & 0.25 / 0.25 & 0.5 / 1 & 99.5 / 99.6 & -/-\\ Vancomycin & 0.5 / 0.5 & 1/1 & 100.0 / 99.6 & 100.0 / 100.0 \end{array}$ a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c = no criteria published d. Criteria at ≤0.06 µg/ml for both organizations.		Clindamycin	≤0.25/≤0.25	≤0.25/0.5	90.2 / 88.6	91.6 / 90.9	
Daptomycin 0.25/0.25 0.5/1 99.5 / 99.6 - / - Vancomycin 0.5/0.5 1/1 100.0 / 99.6 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c. - = no criteria published d. Criteria at ≤0.06 µg/ml for both organizations.		Levofloxacin	1/1	2/2	95.8 / 90.2	-/-	
vancomycin 0.5/0.5 1/1 100.0 / 99.6 100.0 / 100.0 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c. - = no criteria published d. Criteria at ≤0.06 µg/ml for both organizations.		Daptomycin	0.25/0.25	0.5/1	99.5 / 99.6	-/-	
 a. Interpretive breakpoint criteria of the CLSI and EUCAST (2010). b. Amox/clav = amoxacillin/clavulanic acid; TMP/SMX = trimethoprim/sulfamethoxazole; CoNS = coagulase-negative staphylococci c = no criteria published d. Criteria at ≤0.06 µg/ml for both organizations. 		vancomycin	0.5/0.5	1/1	100.0 / 99.6	100.0 / 100.0	
 anoxiciav = anoxacilin/clavularic acid, TMP/SMX = trimethoprim/suitamethoxazole; CoNS = coagulase-hegative staphylococci c = no criteria published d. Criteria at ≤0.06 µg/ml for both organizations. 	a. Interpretive break	point criteria of the C		(2010).	nothovozola, CaNO -		
c = no criteria published d. Criteria at ≤0.06 μg/ml for both organizations.	b. Amox/ciav = amoxaciiin/ciavuianic acio; TMP/SMX = trimetnoprim/suitamethoxazole; CoNS = coagulase-negative staphylococci						
d. Criteria at ≤0.06 μg/ml for both organizations.	c = no criteria publ	lished					
	d. Criteria at ≤0.06 µ	g/ml for both organiz	zations.				

• Among the tested *S. pneumoniae*, non-susceptible penicillin rates (MIC, $\geq 2 \mu g/mI$) were greatly increased in 2009 for the ZAAPS Program (30.7%; 11.5% in 2008), but remained stable in the LEADER Program (21.5%; 22.0%)

• Linezolid MIC_{50/90} values among all streptococci in both programs was consistent at 1 µg/ml. Similar to 2008, all streptococci isolates were susceptible to linezolid

 The most common linezolid resistance mechanisms were G2576T mutations (20) and cfr gene (8), see Table 2.

• The overall linezolid resistance rates for each study were only 0.14% (ZAAPS) and 0.34% (LEADER), with nearly all MIC values occurring at 0.5, 1 or $2 \mu g/ml$ (Figure 1).

Table 1. Linezolid activity as measured by the ZAAPS/LEADER
 Programs (2009) for 12,168 Gram-positive pathogens, and compared to selected other antimicrobials (7-9) by reference (CLSI)
 Table 2. Listing of various linezolid non-susceptible Gram-positive
 cocci detected in ZAAPS and LEADER medical centers during the 2009 ZAAPS resistance surveillance program.

Program	Organism	City	Country	Linezolid MIC (MIC) ^a	Mechanism	
ZAAPS	S. cohnii	Guadalajara	Mexico	>8 (32)	cfr	
	S. epidermidis	Guadalajara	Mexico	>8 (32)	cfr	
	S. epidermidis	Guadalajara	Mexico	>8 (32)	cfr	
	S. epidermidis	Roma	Italy	8	cfr	
	E. faecium	Seoul	Korea	>8 (32)	G2576T	
	E. faecium	Frankfurt	Germany	>8 (16)	G2576T	
	E. faecalis	Frankfurt	Germany	8	G2576T	
	E. faecalis	Shenzhen	China	8	G2576T	
LEADER	S. aureus	Akron	Ohio	8 (16)	cfr	
	S. aureus	Palo Alto	California	>8 (16)	G2576T	
	S. aureus	Hartford	Connecticut	8 (8)	L3 (S145 deletion)	
	S. aureus	Louisville	Kentucky	>8 (16)	cfr	
	S. aureus	Wichita	Kansas	>8 (16)	G2576T	
	S. epidermidis	Akron	Ohio	>8 (128)	G2576T	
	S. epidermidis	Memphis	Tennessee	8 (8)	L3 (V154L, L101V, A157R), L4 (P171S)	
	S. epidermidis	Tempe	Arizona	>8 (>128)	cfr	
	S. epidermidis	Tempe	Arizona	>8 (32)	G2576T	
	S. epidermidis	Lexington	Kentucky	8 (16)	L3 (A157R, L101V, V154L)	
	S. epidermidis	St. Paul	Minnesota	>8 (32)	G2576T	
	S. epidermidis	Detroit	Michigan	>8 (16)	L3 (H146Q)	
	S. capitis	Detroit	Michigan	8 (8)	cfr	
	S. epidermidis	Boston	Massachusetts	>8 (16)	L3 (H146Q)	
	S. epidermidis	New Brunswick	New Jersey	>8 (128)	G2576T	
	S. epidermidis	Salt Lake City	Utah	>8 (128)	G2576T	
	S. epidermidis	Houston	Texas	>8 (128)	G2576T	
	E. faecium	Louisville	Kentucky	>8 (32)	G2576T	
	E. faecium	Louisville	Kentucky	8 (16)	G2576T	
	E. faecium	Louisville	Kentucky	8 (8)	G2576T	
	E. faecium	Louisville	Kentucky	8 (8)	G2576T	
	E. faecium	Wichita	Kansas	>8 (16)	G2576T	
	E. faecium	Charlottesville	Virginia	8 (8)	G2576T	
	E. faecium	Salt Lake City	Utah	8 (16)	G2576T	
	E. faecium	Seattle	Washington	>8 (8)	G2576T	
a. MIC from a reference frozen-form panel with a MIC linezolid range to 128 µg/ml.						

Figure 1. Linezolid MIC distribution for all isolates in the 2009 ZAAPS and LEADER Programs (12,168 strains).





IDSA 2010

JMI Laboratories North Liberty, IA, USA www.jmilabs.com 319.665.3370, 319.665.3371 ronald-jones@jmilabs.com

CONCLUSIONS

- Worldwide linezolid resistance remains unusual (<0.3%) and focused among staphylococci (CoNS > S. aureus) and two species of enterococci (Table 2).
- Linezolid-resistant strains were observed in five countries (Germany, Italy, Mexico, Korea and China) and 15 different states in the USA with clonal occurrences documented in several medical centers.
- A wide variety of resistance mechanisms were identified in 2009, including rRNA target site mutation G2576T, cfr, and L3 and L4 mutations/deletions (Table 2).
- As other commonly used antimicrobials become compromised by evolving resistances, linezolid refractory strains continue to be relatively rare and without escalating occurrence.

ACKNOWLEDGEMENT

The authors would like to thank all participating centers worldwide for contributing isolates to this surveillance protocol. This study was sponsored by an educational/research grant from Pfizer Inc. (New York, NY). Appreciation is also expressed to Ikeda Fumiaki, MPH, Ph.D; Fukui Fasuo, M.D.; Uchino Utsuki, MT; and Intetsu Kobayashi, Ph.D. who coordinated the medical centers that participated in Japan.

REFERENCES

- 1. Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN (2005). Trends in linezolid susceptibility patterns: Report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 26: 13-21.
- 2. Clinical and Laboratory Standards Institute (2009). M7-A8, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard eighth edition. Wayne, PA: CLSI.
- 3. Clinical and Laboratory Standards Institute (2010). M100-S20-U, Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Wayne, PA: CLSI.
- 4. Diekema DJ and Jones RN (2001). Oxazolidinone antibiotics. Lancet 358: 1975-1982. 5. Jones RN, Fritsche TR, Sader HS and Ross JE (2007). Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect. Dis. 59: 199-209.
- 6. Jones RN, Kohno S, Ono Y, Ross JE and Yanagihara K (2009). ZAAPS International Surveillance Program (2007) for linezolid resistance: Results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64: 191-201, 2009.
- 7. Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I and Turnidge JD (2009). Zyvox Annual Appraisal of Potency and Spectrum program: Linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis. 65: 404-413.
- 8. Jones RN, Ross JE, Fritsche TR, Sader HS (2006). Oxazolidinone susceptibility patterns in 2004: Report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57: 279-
- 9. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S and Vester B (2006). The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50: 2500-2505
- 10. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN (2008). First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
- 11. Ross JE, Anderegg TR, Sader HS, Fritsche TR and Jones RN (2005). Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52: 53-58.
- 12. Ross JE, Fritsche TR, Sader HS and Jones RN (2007). Oxazolidinone susceptibility patterns for 2005: International report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents 29: 295-301.